Both bevacizumab and ranibizumab were originally developed by the same company, Genentech.
Notes on verification
Multiple independent sources including drug approval histories, clinical trial registries, and a first-hand account by a key researcher confirm both drugs were developed by Genentech, with ranibizumab derived from the same antibody as bevacizumab. [cascade flags: wikipedia_dropped_other_sources_exist | tier=silver indep_score=0.85 clusters=5 claim_tier=notable | kind=empirical eligibility=high]
Sources
- Procedura di infrazione da parte dell'Autorità Antitrust (seed:health_and_medicine)
- https://www.drugs.com/history/avastin.html (corroboration)
- https://clinicaltrials.gov/study/NCT01127360 (corroboration)
- https://retinatoday.com/articles/2009-may-june/0609_05-php (corroboration)
- https://gabionline.net/biosimilars/general/Biosimilars-of-ranibizumab (corroboration)
- https://www.biospace.com/fda-approves-genentech-s-lucentis-ranibizumab-injection-0-3-mg-prefilled-syringe-for-diabetic-macular-edema-and-diabetic-retinopathy (corroboration)
- https://www.drugs.com/history/lucentis.html (corroboration)